Therapeutics (TGTX) 2025 Earnings Outlook for Investors
TG Therapeutics faces a pivotal year as it closes 2025 with a tighter focus on its flagship therapeutics portfolio an...
Mistakes disrupt budgets and derail goals. Explore how small oversights impact finances and how to recalibrate for stable, predictable spending.
27,871 articlesTG Therapeutics faces a pivotal year as it closes 2025 with a tighter focus on its flagship therapeutics portfolio an...
Viktor has raised $75 million in a Series A to deploy an AI coworker inside Slack and Teams, aiming to automate repet...
Rising volatility and inflation are driving more households to consider early Social Security claims. Taking benefits...
Microsoft stock has fallen about 27% from its all-time high, but long‑term catalysts could help it double by 2030. Th...
A focused look at a nuclear energy stock with small modular reactors (SMRs) at the center. Learn the potential upside...
In a choppy 2026 market, a momentum-focused ETF is gaining attention for its track record of catching leaders while a...
As markets wobble in mid-2026, investors are increasingly pursuing steady dividend cash flow to supplement earnings. ...
The market loves dramatic headlines about AI threatening legacy tech, but the real story is nuanced. This piece expla...
The Janus Henderson AAA CLO ETF draws buyers with a high yield and AAA label, but a hidden tail-risk dynamic could er...
In Q1 2026, Duquesne Family Office quietly expanded its South American equity bets, signaling a macro-led stance that...
Discover how Remax RMAX 2025 earnings shape the company’s growth story. We break down revenue drivers, margins, and k...
When a cybersecurity giant bets $25 billion on a single platform, investors should understand the why, the potential ...